“We will focus on research and development for anti-cancer and immune disease treatments.”
Dong-A ST’s core research personnel communicated directly with analysts and presented Dong-A ST’s R&D blueprint.
Dong-A ST announced on the 15th that it held ‘Dong-A ST R&D day 2024’ for domestic securities analysts at its headquarters in Yongdu-dong, Dongdaemun-gu, Seoul on the 14th.
At the event, Dong-A ST R&D President Park Jae-hong, R&D Strategy Director Yoo Jun-su, and Research Division Director Kim Mi-kyung directly presented Dong-A ST’s R&D performance, future plans, and pipeline to analysts, informing them of Dong-A ST’s competitiveness.
Yoo Jun-su, head of R&D Strategy Department, started with a welcome speech and introduced the product development process, growth potential, market size and competitor status, and special advantages of Stelara biosimilar ‘Imuldosa’. Stelara ingredient ustekinumab is a drug that recorded sales of $20.323 billion worldwide last year. Last October, Dong-A ST demonstrated its global-level R&D capabilities by obtaining product approval for Imuldosa from the U.S. Food and Drug Administration (FDA) and a recommendation for product approval from the European Committee for Medicinal Products for Human Use (CHMP).
Next, Director Kim Mi-kyung of the Research Division discussed the clinical progress status, future schedule, and possibility of success of ‘DA-1726’, an obesity treatment drug, and ‘DA-1241’, a treatment for metabolic abnormality-related steatohepatitis (MASH), which are currently undergoing clinical trials through its U.S. subsidiary Neurobo Pharmaceuticals. Diagnosed.
DA-1726 is a new drug candidate being developed as an oxyntomodulin analogue-based obesity treatment. It acts simultaneously on the GLP-1 receptor and glucagon receptor to suppress appetite and promote insulin secretion, leading to weight loss and blood sugar control. Part 2 of the global clinical trial is in progress, and clinical results are scheduled to be released in the first quarter of 2025. DA-1241 is a new drug candidate being developed as a treatment for MASH. DA-1241 is undergoing global phase 2 clinical trials, Parts 1 and 2, and is scheduled to conclude in the second half of this year.
Next, Jaehong Park, President of R&D, discussed the competitiveness, development status, and future plans of major clinical assets such as Dong-A ST’s entire pipeline, immunotherapy drug ‘DA-4505’ and dementia treatment drug ‘DA-7503’, and Aptis ADC linker platform ‘AbClick’. )’s technological excellence and expansion potential, and the development strategy of ‘DA-3501(AT-211)’.
In particular, the company plans to focus on its own research and development for anti-cancer and immune disease treatments as part of its mid- to long-term R&D plan, and plans to expand its pipeline by introducing external new drugs. He also emphasized that he will accelerate the transition from new drug development centered on small molecule compounds to research and development of ADC and new modalities.
Lastly, in order to establish a virtuous cycle of research and development investment, the company explained that it plans to secure short-term revenue sources through internalization of platforms such as drug delivery systems and target protein degradation (TPD)-based technologies, external partnering, and development of improved new drugs.
Jaehong Park, President of R&D, said, “This R&D day was a meaningful time to communicate directly with analysts and inform them of Dong-A ST’s R&D blueprint in detail.” He added, “Through the development of innovative new drugs, we will establish ourselves as a global R&D pharmaceutical company beyond Korea.” “We will focus our research capabilities to make this happen,” he said.
Source: kormedi.com
